Drug targets in cancer Flashcards

(26 cards)

1
Q

3 stages of cell cycle check points

A

G1/S
G2/M
M

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

G1/S check point regulated by

A

retinoblastoma protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

G2/M checkpoint regulated by

A

p53 (transcription factor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

M checkpoint

A

ensures proper attachment of chromasomes to mitotic spindle. If no proper attachment then cell death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Different types of anti-cancer drugs

A

Chemotherapy
ENdocrine therapy
Molecular targeted therapy
Immunotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Oncogene addiction

A

When an oncogene uses one signalling transduction pathway.

E.g. HER2 (Breast Ca), BRAF (melanoma) EGFR and ALK (non small cell LC), BCR-ABL (CML)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Synthetic lethality

A

loss of function of either 2 or more gene individually has limited effect, but loss of function in both genes leads to cell death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cancer targets can be found by

A

Immunohistochemistry
Insitu hybridisation
Next generation sequencing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Re: Molecular targeting agents

what is on target effects?

A
  • side effects that are mechanism based.
  • can be used as clinical biomarkers.
  • e.g. sunitib = HTN
  • gefitinib = rash
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Re: molecular targeting agents

What is off target effects

A
  • side effect that are caused by inhibition of other targets
  • immune reactions
  • toxic metabolites
  • expression in ormal tissues
  • chemo side effect: mucositis etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What down stream signalling pathway does Tyrosine Kinase use?

A

Ras -> Raf -> MEK -> ERK

and

P13K -> AKt -> mTOR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Examples of tyrosine kinase receptors

A

ERBB/HER family
Often gain of function mutation

e.g. ERBB1 = EGFR
ERBB2 = HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Monoclonal antibodies for EGFR and its side effect

A

Cetuximab and panitumumab

acneiform rash, diarrhoea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Examples of TKIs for EGFR

A

Erlotinib, gefitinib (1st generation), afatinib (2nd generation)

side effect: rash, diarrhoea, fatigue, transaminitis.

Treat skin toxicity with: sun protection, oral antibiotics, skin care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is osimertinib?

A

3rd generation EGFR TKI effective against T790M mutation and sensitising mutation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Side effect of osimertinib

A

less skin side effect than 1-2nd line TKIs.

17
Q

Monoclonal antibodies against HER2 in breast ca

A

Trastuzumab and pertuzumab.

side effect: cardiotoxicity

18
Q

Lapatinib

A

Dual EGFR/HER2 TKI

S/E: N/V/D, mucositis, fatigue

19
Q

WHat is Trastuzumab-emtansine?

A

antibody drug conjugate for HER2+ mBC cancer.

S/E: well tolerated, thrombocytopenia/raised aminotransferase

20
Q

Examples of VEGF receptor and multikinase inhibitor

A
"-inib"
Sorafenib
Sunitinib
Pazopanib
Axitinib
Cabozantinib
Lenvatinib
Vandetanib
21
Q

Side effect of multikinase inhibitors

A

VEGF related: HTN, proteinuria, thromboembolism, RPLES

GI, skin, transaminitis/thyroid dysfunction.

22
Q

How do you target Cyclin D/CDK/Rb in the cell cycle as part of cancer treatment?

A

(CDK4/6 + Cyclin D) phosphorylate and inactivate tumour suppressor Rb.

Inhibition of CD4/CD6 leads to reactivation of Rb and cell cycle arrest at G1.

23
Q

What is ribociclib?

A

Selective CD4/6 inhibitor
Given orally w/ aromatase inhibitor.

S/E: neutropenia, LFT derangement, diarrhoea

24
Q

Mechanism of action of PARP inhibitor

A
  • PARP -> repair ss DNA break.
  • ds DNA repair via homologous recombination (BRCA)
  • if PARP is inhibited, then cells rely on homologous recombination to repair cells. If BRCA is mutated, they can’t fix dsDNA break so this leads to cell death.
25
Olaparib
PARP inhibitor TO treat platinum sensitive relapse BRCA+ ovarian, fallopian tube, primary peritoneal cancer. S/E: nausea, diarrhoea, fatigue
26
Mechanism of drug resistance in cancer
- Primary/intrinsic - Secondary via: tumour heterogeneity, activation of alternative pathway, alteration of drug target, reactivation of pathway